Occidental is now a more concentrated upstream and carbon-management company after agreeing to sell OxyChem to Berkshire Hathaway for $9.7 billion, with most proceeds earmarked for debt reduction below $15 billion.
While this improves balance sheet resilience, it also removes a countercyclical cash generator and increases exposure to commodity prices.
The company ended Q3 2025 with $20.8 billion of principal debt, ~$2.2 billion of cash, and 985 million common shares outstanding, and generated TTM free cash flow of roughly $3.8–4.0 billion using the last four reported quarters.
Strategically, Oxy’s competitive edges are scale and technical know‑how in the Permian (including EOR) plus a head start in direct air capture through 1PointFive’s STRATOS plant, which secured EPA Class VI sequestration permits and has multiple offtake agreements.
These advantages are real but not equivalent to durable network effects or high switching costs. The moat is moderate, pricing power is limited by commodity dynamics, and predictability is constrained by oil and gas cycles, though debt paydown and cost reductions help.
Our quality view is mixed overall: solid assets and promising carbon projects, counterbalanced by cyclicality, residual leverage, preferred obligations and the pending loss of OxyChem’s diversification.
Intangible assets: moderate. Occidental’s EOR know‑how, subsurface capability, and carbon management expertise are genuine and hard‑to‑replicate, but not patent‑protected monopolies (score ~60).
Cost advantages: decent where Oxy operates at scale in the Permian, and management highlights structural opex reductions; still, many peers now operate efficiently, so advantage is relative, not absolute (score ~60). Switching costs: negligible for commodity buyers (score ~20).
Network effects: none in upstream; a potential proto‑network could emerge around sequestration hubs and Class VI permitted storage, but it is early and competitive (score ~25). Efficient scale: some in CO2 pipeline/EOR infrastructure and sequestration reservoirs where permits and geology are finite (score ~55).
Weighted together, we view the moat as moderate and execution‑dependent, not entrenched.
Oxy remains a price taker for oil, NGLs and gas. Marketing and midstream can enhance realizations at the margin, and OxyChem historically provided some countercyclical buffer, but that business is being sold.
The emerging carbon‑removal segment could command premium pricing under 45Q and through long‑dated CDR contracts, yet volumes are nascent and capital intensity is high, so latent pricing power is unproven. Overall pricing leverage is limited today.
Cash flows remain tied to commodity cycles. TTM production execution is solid (Q3 2025 production exceeded the high end of guidance at ~1,465 Mboe/d), but revenue and earnings fluctuate with prices and differentials. The pending sale of OxyChem reduces diversification, further increasing exposure to upstream volatility.
The DAC pathway offers a potential, policy‑supported, multi‑year revenue stream, yet timing and unit economics are still evolving. Geographic risk is manageable with a U.S. focus plus MENA assets under long‑lived agreements.
At September 30, 2025, total borrowings at face value were ~$20.8B and cash was ~$2.2B. Management repaid $1.3B in Q3 and expects to use ~$6.5B of OxyChem proceeds to push principal debt below $15B. Ratings sit at Baa3/BBB-/BB+ (Moody’s/Fitch/S&P), with Fitch outlook recently positive; preferred dividends remain a sizable cash claim.
Net leverage is improving, liquidity is adequate, and the debt ladder has been actively managed, but absolute leverage and preferred obligations constrain flexibility versus best‑in‑class peers.
Recent priorities have been deleveraging and focused capex. Execution includes asset sales (e.g., DJ Basin minerals), warrant‑exercise cash applied to maturities, and capex guidance reductions.
The CrownRock acquisition added high‑quality Midland inventory but increased leverage; the OxyChem divestiture accelerates de‑risking but sacrifices diversification. Share repurchases were minimal in 2025 given debt targets; the dividend has been raised to $0.24/quarter.
Track record is mixed since Anadarko, yet recent discipline and debt reduction are positives.
CEO Vicki Hollub delivered large strategic moves (Anadarko, CrownRock, OxyChem sale) and positioned Oxy early in DAC. Berkshire Hathaway’s continuing stake and relationship provide both validation and optionality, though preferred dividends and warrants reflect expensive 2019 financing.
Communication on debt targets, capex discipline and cost reductions has been consistent, but the overall record blends bold bets with elevated financial risk through the cycle.

Is Occidental Petroleum a good investment at $53?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.